Molecular Medicine

, Volume 10, Issue 1–6, pp 55–62 | Cite as

Epigallocatechin, a Green Tea Polyphenol, Attenuates Myocardial Ischemia Reperfusion Injury in Rats

  • Rajesh Aneja
  • Paul W. Hake
  • Timothy J. Burroughs
  • Alvin G. Denenberg
  • Hector R. Wong
  • Basilia Zingarelli


Epigallocatechin-3-gallate (EGCG) is the most prominent catechin in green tea. EGCG has been shown to modulate numerous molecular targets in the setting of inflammation and cancer. These molecular targets have also been demonstrated to be important participants in reperfusion injury, hence this study examines the effects of EGCG in myocardial reperfusion injury. Male Wistar rats were subjected to myocardial ischemia (30 min) and reperfusion (up to 2 h). Rats were treated with EGCG (10 mg/kg intravenously) or with vehicle at the end of the ischemia period followed by a continuous infusion (EGCG 10 mg/kg/h) during the reperfusion period. In vehicle-treated rats, extensive myocardial injury was associated with tissue neutrophil infiltration as evaluated by myeloperoxidase activity, and elevated levels of plasma creatine phosphokinase. Vehicle-treated rats also demonstrated increased plasma levels of interleukin-6. These events were associated with cytosol degradation of inhibitor κB-α, activation of IκB kinase, phosphorylation of c-Jun, and subsequent activation of nuclear factor-κB and activator protein-1 in the infarcted heart. In vivo treatment with EGCG reduced myocardial damage and myeloperoxidase activity. Plasma IL-6 and creatine phosphokinase levels were decreased after EGCG administration. This beneficial effect of EGCG was associated with reduction of nuclear factor-κB and activator protein-1 DNA binding. The results of this study suggest that EGCG is beneficial for the treatment of reperfusion-induced myocardial damage by inhibition of the NF-κB and AP-1 pathway.



Supported by NIH grant T 32 GM08478 (RA), RO1GM061723 (HRW), and NIH RO1HL 60730 (BZ).


  1. 1.
    Hearse DJ. (1991) Reperfusion-induced injury: a possible role for oxidant stress and its manipulation. Cardiovasc. Drugs Ther. 5 Suppl 2:225–35.CrossRefGoogle Scholar
  2. 2.
    Gross GJ, Farber NE, Hardman HF, Warltier DC. (1986) Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am. J. Physiol. 250:H372–7.PubMedGoogle Scholar
  3. 3.
    Poltronieri R, Cevese A, Sbarbati A. (1992) Protective effect of selenium in cardiac ischemia and reperfusion. Cardioscience 3:155–60.PubMedGoogle Scholar
  4. 4.
    Ferrari R et al. (1998) Oxidative stress during myocardial ischaemia and heart failure. Eur. Heart J. 19 Suppl B:B2–11.PubMedGoogle Scholar
  5. 5.
    Grisham MB, Granger DN, Lefer DJ. (1998) Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radic. Biol. Med. 25:404–33.CrossRefGoogle Scholar
  6. 6.
    Ambrosio G, Tritto I. (1999) Reperfusion injury: experimental evidence and clinical implications. Am. Heart J. 138:S69–75.CrossRefGoogle Scholar
  7. 7.
    Mukaida N, Okamato S, Ishikawa Y, Matsushima K. (1994) Molecular mechanisms of interleukin-8 gene expression. Leukoc. Biol. J. 56:554–8.CrossRefGoogle Scholar
  8. 8.
    DiDonato JA. Hayakawa M, Rothwarf DM, Zandi E, Karin M. (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388:548–54.CrossRefGoogle Scholar
  9. 9.
    Mercurio F, Zhu H, Murray BW. (1997) IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278:860–6.CrossRefGoogle Scholar
  10. 10.
    Karin M, Ben-Neriah Y. (2000) Phosphorylation meets ubiquitination:the control of NF-kB activity. Annu. Rev. Immunol. 18:621–63.CrossRefGoogle Scholar
  11. 11.
    Karin M. (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270:16483–6.CrossRefGoogle Scholar
  12. 12.
    Duffy SJ, Vita JA, Holbrook M, Swerdloff PL, Keaney JF, Jr. (2001) Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21:1084–9.CrossRefGoogle Scholar
  13. 13.
    Duffy SJ et al. (2001) Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104:151–6.CrossRefGoogle Scholar
  14. 14.
    Lin JK, Liang YC, Lin-Shiau SY. (1999) Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem. Pharmacol. 58:911–5.CrossRefGoogle Scholar
  15. 15.
    Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK. (2000) Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. Biochem. Pharmacol. 59:357–67.CrossRefGoogle Scholar
  16. 16.
    Wang ZY et al. (1994) Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res. 54:3428–35.PubMedGoogle Scholar
  17. 17.
    Serafini M, Ghiselli A, Ferro-Luzzi A. (1996) In vivo antioxidant effect of green and black tea in man. Eur. J. Clin. Nutr. 50:28–32.PubMedGoogle Scholar
  18. 18.
    Dona M et al. (2003) Neutrophil restraint by green tea: Inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 170:4335–41.CrossRefGoogle Scholar
  19. 19.
    Kang WS et al. (1999) Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb. Res. 96:229–37.CrossRefGoogle Scholar
  20. 20.
    Levites Y, Amit T, Youdim MB, Mandel S. (2002) Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J. Biol. Chem. 277:30574–80.CrossRefGoogle Scholar
  21. 21.
    Levites Y, Youdim MB, Maor G, Mandel S. (2002) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63:21–9.CrossRefGoogle Scholar
  22. 22.
    Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. (1997) Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 89:1881–6.CrossRefGoogle Scholar
  23. 23.
    Chan MM, Fong D, Ho CT, Huang HI. (1997) Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. Biochem. Pharmacol. 54:1281–6.CrossRefGoogle Scholar
  24. 24.
    Levites Y, Amit T, Mandel S, Youdim MB. (2003) Neuroprotection and neurorescue against Abeta toxicity and protein kinase C-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallo-catechin-3-gallate. FASEB J. 17:952–4.CrossRefGoogle Scholar
  25. 25.
    Kim HS et al. (2004) EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res. 24:747–53.PubMedGoogle Scholar
  26. 26.
    Tedeschi E, Suzuki H, Menegazzi M. (2002) Antiinflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. Ann. N.Y. Acad. Sci. 973:435–7.CrossRefGoogle Scholar
  27. 27.
    Chen PC et al. (2002) A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 26:233–41.CrossRefGoogle Scholar
  28. 28.
    Zingarelli B, Cuzzocrea S, Zsengeller Z, Salzman AL, Szabo C. (1997) Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc. Res. 36:205–15.CrossRefGoogle Scholar
  29. 29.
    Mizukami Y, Yoshioka K, Morimoto S, Yoshida K. (1997) A novel mechanism of JNK1 activation. Nuclear translocation and activation of JNK1 during ischemia and reperfusion. J. Biol. Chem. 272:16657–62.CrossRefGoogle Scholar
  30. 30.
    Zingarelli B, Hake PW, Yang Z, O’Connor M, Denenberg A, Wong HR. (2002) Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage. FASEB J. 16:327–42.CrossRefGoogle Scholar
  31. 31.
    Nose P. (1993) Cytokines and reperfusion injury. J. Card. Surg. 8:305–8.CrossRefGoogle Scholar
  32. 32.
    Wisdom R. (1999) AP-1: one switch for many signals. Exp. Cell. Res. 253:180–5.CrossRefGoogle Scholar
  33. 33.
    Mitsos SE et al. (1986) Protective effects of N-2-mercaptopropionyl glycine against myocardial reperfusion injury after neutrophil depletion in the dog: evidence for the role of intracellular-derived free radicals. Circulation 73:1077–86.CrossRefGoogle Scholar
  34. 34.
    Duilio C et al. (2001) Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 280:H2649–57.CrossRefGoogle Scholar
  35. 35.
    Katiyar SK, Mukhtar H. (2001) Green tea polyphenol (-)-epigallocatechin-3-gallate treatment to mouse skin prevents UVB-induced infiltration of leukocytes, depletion of antigen-presenting cells, and oxidative stress. J. Leukoc. Biol. 69:719–26.PubMedGoogle Scholar
  36. 36.
    Katiyar SK, Matsui MS, Elmets CA, Mukhtar H. (1999) Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem. Photobiol. 69:148–53.PubMedGoogle Scholar
  37. 37.
    Zandi E, Karin M. (1999) Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. Mol. Cell Biol. 19:4547–51.CrossRefGoogle Scholar
  38. 38.
    Yang F et al. (2001) The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol. 60:528–33.CrossRefGoogle Scholar
  39. 39.
    Suzuki YJ, Packer L. (1993) Inhibition of NF-kappa B activation by vitamin E derivatives. Biochem. Biophys. Res. Commun. 193:277–83.CrossRefGoogle Scholar
  40. 40.
    Beauparlant P, Hiscott J. (1996) Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7:175–90.CrossRefGoogle Scholar
  41. 41.
    L’Allemain G. (1999) Multiple actions of EGCG, the main component of green tea. Bull. Cancer 86:721–4.PubMedGoogle Scholar
  42. 42.
    Zingarelli B et al. (2004) Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am. J. Physiol. Heart Circ. Physiol. 286:H1408–15.CrossRefGoogle Scholar
  43. 43.
    Stein B et al. (1993) Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 12:3879–91.CrossRefGoogle Scholar
  44. 44.
    Clemens JA, Stephenson DT, Smalstig EB, Dixon EP, Little SP. (1997) Global ischemia activates nuclear factor-kappa B in forebrain neurons of rats. Stroke 28:1073–80; discussion 1080–71.CrossRefGoogle Scholar
  45. 45.
    Zwacka RM et al. (1998) Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nat. Med. 4:698–704.CrossRefGoogle Scholar
  46. 46.
    Menegazzi M et al. (2001) Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. FASEB J 15:1309–11.CrossRefGoogle Scholar
  47. 47.
    Watson JL et al. (2004) The green tea polyphenol epigallocatechin gallate blocks epithelial barrier dysfunction provoked by IFNγ but not by IL-4. Am. J. Physiol. Gastrointest. Liver Physiol Jul 1[Epub ahead of print].Google Scholar
  48. 48.
    Sesso H, Gaziano J, Buring J, Hennekens C. (1999) Coffee and tea intake and the risk of myocardial infarction. Am. J. Epidemiol. 149:162–7.CrossRefGoogle Scholar
  49. 49.
    Cheng TO. (2000) Tea is good for the heart. Arch. Intern. Med. 160:2397.CrossRefGoogle Scholar
  50. 50.
    Geleijnse JM, Launer LJ, Hofman A, Pols HAP, Witteman JCM. (1999) Tea flavonoids may protect against atherosclerosis: The Rotterdam study. Arch. Intern. Med. 159:2170–4.CrossRefGoogle Scholar
  51. 51.
    Hakim IA AM, Alduwaihy M, Al-Rubeaan K, Al-Nuaim AR, Al-Attas OS. (2003) Tea consumption and the prevalence of coronary heart disease in Saudi adults: results from a Saudi national study. Prev. Med. 36(1):64–70.CrossRefGoogle Scholar
  52. 52.
    Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. (2002) Tea consumption and mortality after acute myocardial infarction. Circulation 105:2476–81.CrossRefGoogle Scholar
  53. 53.
    Chow HH et al. (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 9:3312–9.PubMedGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2004

Authors and Affiliations

  • Rajesh Aneja
    • 1
  • Paul W. Hake
    • 1
  • Timothy J. Burroughs
    • 1
  • Alvin G. Denenberg
    • 1
  • Hector R. Wong
    • 1
  • Basilia Zingarelli
    • 1
  1. 1.Department of Pediatrics, Division of Critical Care Medicine-OSB5, Cincinnati Children’s Hospital Medical Center and College of MedicineUniversity of CincinnatiCincinnatiUSA

Personalised recommendations